120 completed, 34 terminated, 18 active not recruiting, 11 withdrawn. 110 Phase 1, 104 Phase 2, 13 Not applicable, 4 Early Phase 1, 1 Phase 3.
Follow Recurrent Mantle Cell Lymphoma: new trials by email Literature Review of Recurrent Mantle Cell Lymphoma trials Research Report on Recurrent Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2026-09-29 | 2026-10-14 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-07-31 | 2026-08-17 |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy Biospecimen Collection, Computed Tomography, Glofitamab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-07-08 | 2026-09-09 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-08-01 | 2026-02-23 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Hydrochloride, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 8 | 2022-06-29 | 2026-04-20 |
| Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma Eprenetapopt, Venetoclax - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-11-30 | 2022-03-10 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial Biospecimen Collection, Follow-Up - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Not applicable | Completed | M.D. Anderson Cancer Center | 1 | 2021-03-04 | 2025-02-26 |
| Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Acalabrutinib, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 36 | 2020-12-31 | 2026-10-01 |
Showing 20 of 199. Sign in to see all of them.
Lymphoma, Mantle-Cell (199) · Lymphoma, Follicular (151) · Lymphoma, Large B-Cell, Diffuse (147) · Leukemia, Lymphocytic, Chronic, B-Cell (134) · Lymphoma, B-Cell, Marginal Zone (130) · Lymphoma, Non-Hodgkin (112) · Burkitt Lymphoma (104) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (98) · Waldenstrom Macroglobulinemia (96) · Lymphoma, Large-Cell, Immunoblastic (88) · Hodgkin Disease (78) · Lymphoma, Large-Cell, Anaplastic (71) · Mycosis Fungoides (69) · Sezary Syndrome (69) · Lymphoma, T-Cell, Cutaneous (67)
Hemic and Lymphatic Diseases (199) · Immune System Diseases (199) · Immunoproliferative Disorders (199) · Lymphatic Diseases (199) · Lymphoproliferative Disorders (199) · Neoplasms by Histologic Type (199) · Lymphoma (198) · Neoplasms (198) · Lymphoma, B-Cell (150) · Hematologic Diseases (147) · Leukemia (139) · Leukemia, Lymphoid (138) · Disease Attributes (136) · Pathologic Processes (136) · Pathological Conditions, Signs and Symptoms (136)
Rituximab (38) · fludarabine phosphate (27) · Cyclophosphamide (24) · Peripheral Blood Stem Cell Transplantation (24) · Whole-Body Irradiation (20) · Mycophenolic Acid (19) · Bortezomib (16) · Cyclosporine (14) · Lenalidomide (14) · ibrutinib (12) · Etoposide (11) · Biopsy (10) · CT-P10 (10) · Magnetic Resonance Spectroscopy (10) · Tacrolimus (10)
National Cancer Institute (NCI) (69) · Fred Hutchinson Cancer Center (35) · City of Hope Medical Center (18) · M.D. Anderson Cancer Center (9) · Mayo Clinic (9) · Case Comprehensive Cancer Center (6) · Roswell Park Cancer Institute (5) · University of Washington (5) · Chinese PLA General Hospital (4) · Vanderbilt-Ingram Cancer Center (3) · Academic and Community Cancer Research United (2) · Barbara Ann Karmanos Cancer Institute (2) · Kami Maddocks, MD (2) · OHSU Knight Cancer Institute (2) · University of Nebraska (2)
United States (186) · China (7) · Italy (7) · Canada (4) · Germany (4) · Denmark (1)
Ajay Gopal (9) · David Maloney (6) · Brenda Sandmaier (5) · Stephen Ansell (4) · Anas Younes (3) · Brenda Cooper (3) · Kami Maddocks, MD (3) · Paul Martin (3) · Alexey Danilov (2) · Bhagirathbhai Dholaria (2) · Catherine S Diefenbach (2) · Elizabeth Budde (2) · George Chen (2) · John Gerecitano (2)
PMID 34515338, PMID 32499241, PMID 27118452, PMID 18974373, PMID 19900571, PMID 21300924, PMID 21440503, PMID 21508413, PMID 21725056, PMID 22259028, PMID 22308288, PMID 23256542, PMID 23834234, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25085357, PMID 25317870, PMID 25355819, PMID 25444722, PMID 26213141, PMID 26451310, PMID 26640039, PMID 26764356, PMID 26853648, PMID 26943915, PMID 27111235, PMID 28270022, PMID 28314788, PMID 28817727, PMID 28869931, PMID 29038338, PMID 29263894, PMID 29292843, PMID 29572391, PMID 29599530, PMID 29954415, PMID 30454872, PMID 30562587, PMID 30692121, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31076448, PMID 31388792, PMID 31481800, PMID 31617432, PMID 31648294, PMID 31815579, PMID 32245502
P30CA015704 (19), P30CA033572 (11), P30CA015083 (10), U01CA076576 (9), U01CA062502 (7), P50CA107399 (6), U01CA062505 (6), P01CA018029 (5), P30CA016058 (5), P30CA016672 (5), U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), N01CM62202 (4), P01CA044991 (4)